Stockscreener 앱 받기
236.40
1.84%
-4.98
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
This Biopharma Stock Flirts With Buy Point After New FDA Approval - Investor's Business Daily
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 - Sahm
Ascendis Wins FDA Approval For Rare Disease Therapy - Sahm
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference - Sahm
Ascendis Pharma NasdaqGS ASND Revenue Surge Keeps Losses In Focus And Tests Bullish Narratives - Sahm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewswire Inc.
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - Sahm
Ascendis Pharma (ASND) Is Up 5.2% After Revenue Jumps And Losses Narrow In 2025 Results - Sahm
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth - Finviz
Does Stronger 2025 Results And Narrowing Losses Reshape The Bull Case For Ascendis Pharma (ASND)? - Sahm
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - MSN
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Sahm
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript - The Globe and Mail
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss - Chartmill
Ascendis Pharma Earnings Report: Q4 Overview - Sahm
Did Health Canada’s Yorvipath Approval Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - Sahm
Hershey Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Assessing Ascendis Pharma (ASND) Valuation After Health Canada Approval For Yorvipath - Sahm
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT - Finviz
ASCENDIS PHARMA A/SADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum - Chartmill
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Allstate Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Is Positive COACH Data and Priority Review for TransCon CNP Reframing Ascendis Pharma’s (ASND) Investment Case? - Sahm
Ascendis Pharma ADR Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results - Sahm
Ascendis Pharma ADR shows rising price performance with jump to 83 RS rating - MSN
Ascendis Pharma A/S (ASND): A Bull Case Theory - Finviz
Did COACH Trial Combo Data and FDA Priority Review Just Shift Ascendis Pharma's (ASND) Investment Narrative? - Sahm
Ascendis Pharma ADR Shows Rising Price Performance With Jump To 83 RS Rating - Investor's Business Daily
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Phase 2 Achondroplasia Results - Sahm
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Sahm
Ascendis Pharma ADR reaches 80-plus relative strength rating benchmark - MSN
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan - ChartMill
Ascendis Pharma ADR Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Can you now get a good deal on Ascendis Pharma A/S ADR’s shares? - uspostnews.com
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today - Sahm
Ascendis Pharma’s Price Surge Amid New Developments - StocksToTrade
Looking Into Ascendis Pharma AS's Recent Short Interest - Sahm
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - setenews.com
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Sahm
The time has not yet come to remove your chips from the table: Ascendis Pharma A/S ADR (ASND) - setenews.com
Honda Upgraded, McDonald’s Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm
Ascendis Pharma Reports Third Quarter 2025 Financial Results - Sahm
Is the Market Bullish or Bearish on Ascendis Pharma AS? - Sahm
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - Sahm
0.50%
자본화:
|
볼륨(24시간):